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Abstract
Senescence is one of the main barriers against tumor progression. Oncogenic signals in primary cells result in oncogene-
induced senescence (OIS), crucial for protection against cancer development. It has been described in premalignant lesions
that OIS requires DNA damage response (DDR) activation, safeguard of the integrity of the genome. Here we demonstrate
how the cellular mechanisms involved in oncogenic transformation in a model of glioma uncouple OIS and DDR. We use
this tumor type as a paradigm of oncogenic transformation. In human gliomas most of the genetic alterations that have
been previously identified result in abnormal activation of cell growth signaling pathways and deregulation of cell cycle,
features recapitulated in our model by oncogenic Ras expression and retinoblastoma (Rb) inactivation respectively. In this
scenario, the absence of pRb confers a proliferative advantage and activates DDR to a greater extent in a DNA lesion-
independent fashion than cells that express only HRas
V12. Moreover, Rb loss inactivates the stress kinase DDR-associated
p38MAPK by specific Wip1-dependent dephosphorylation. Thus, Rb loss acts as a switch mediating the transition between
premalignant lesions and cancer through DDR modulation. These findings may have important implications for the
understanding the biology of gliomas and anticipate a new target, Wip1 phosphatase, for novel therapeutic strategies.
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Introduction
Cell proliferation is dependent on the appropriate transmission
of growth signals from the cell membrane to the nucleus. Ras
family proteins function as a membrane-associated biologic switch
that relays signals from ligand-stimulated receptors to cytoplas-
matic downstream effectors proteins like phosphoinositide 3-kinase
(PI3K) and Raf-MEK1/2. These protein-kinases are responsible
of phosphorylation of transcription factors, which in last instance
contribute to proliferation, differentiation and cell survival. The
importance of the Ras/Raf/MEK/ERK pathway in growth
control is further supported by the fact that hyperactivation of this
pathway is usually found associated with many human tumors
such as gliomas.
Gliomas are the most common primary tumors in the brain and
are divided into four clinical grades on the basis of their histology
and prognosis [1]. Several gene expression alterations and
chromosomal abnormalities are commonly found in gliomas,
and in some cases these mutations correlate with clinical grade.
One common alteration in gliomas of all grades is the
overproduction of growth factors such as FGF2, EGFR and
PDGF19, and their receptors. Interestingly, although mutations in
Ras are not found in gliomas, overexpression and/or gain-of-
function mutations in several growth factor receptors increase Ras
activity [2–4], activating downstream effectors like Raf/MEK/
ERK and PI3K/AKT pathways [5]. Indeed, several mouse
models of glioma have causally implicated activated HRas and
KRas in glioma formation [6–8].
Deregulation of signal transduction pathways mutations is found
both in low- and high-grade gliomas, whereas other mutations are
predominantly found in one or another group of gliomas. Thus,
nearly all WHO grade III and IV (GBM) show a disruption of cell
cycle due to alterations in one out of three genetic loci governing
G1 arrest such as: CDK4, INK4a–ARF or Rb. Over half of high-
grade human gliomas lack a functional INK4a–ARF locus [9,10]
and hence can produce neither p16
INK4a nor p19
ARF, the two
proteins encoded by this locus [11]. Most of the remaining gliomas
either demonstrate a great amplification of the CDK4 locus or lack
the Rb gene [12–14] conjointly, in some cases, with p53 alterations
[15].
Curiously, in human and rodent cells, oncogenic signals result in
a permanent G1 arrest known as OIS [16,17]. Although diverse
stimuli can induce a senescence response, they appear to converge
on p16
INK4a/pRb and/or p19
ARF/p53 pathways that establish
and maintain the senescence growth arrest. In fact, increased
expression levels of p53, p19
ARF and p16
INK4a have been found in
murine cells undergoing OIS, as well as in some human
premalignant neoplastic lesions [18–21].
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which leads to activation of the DNA damage response (DDR).
This response includes phosphorylation of kinases such as ATM
and Chk2, histone H2AX and p53 [19,20,22], which ultimately
force the cell to undergo oncogene-induced senescence (OIS). Like
apoptosis, OIS is a tumor-suppressing defense mechanism that
must be compromised for tumorigenesis to occur.
In the same way, recent studies have revealed a major role of
the p38MAPK pathway in OIS caused by oncogenic Ras [23,24].
Although, part of the tumor-suppressive function of p38MAPK is
attributed to its ability to mediate apoptosis as a result of ROS
accumulation induced by activated oncogenes [25].
Here, we have developed a new model for gliomagenesis in
hopes of understanding these patterns and discerning the
contributions made to tumor formation. Similar approaches have
been used before by other groups to recreate the behavior of
glioma cells introducing in astrocytes some of the genetic lesions
mentioned above [26–28]. We demonstrate that astrocytes are
resistant to Ras-induced senescence in presence of high levels of
ROS and DNA damage despite DDR activation. Moreover, in
this context, loss of Rb locus favors the progression of low-grade
gliomas to higher-grade tumors by conferring a double selective
advantage to the tumor. First, deregulation of the pRb-E2F1
pathway is able to stimulate DDR activation through activation of
ATM to phosphorylate p53 without increasing DNA double-
strand breaks (DSBs) or ROS production [29]. This preferential
activation of the DNA damage response increases DNA repair
capacity that is essential for tumor cell survival. Finally, loss of Rb
locus negatively regulates p38MAPK phosphorylation. Down-
regulation of the p38MAPK signaling pathway is achieved
through E2F-induced up-regulation of Wip1, a specific phospha-
tase that dephosphorylates and inactivates p38MAPK [30], also
favoring the progression to astrocyte transformation.
Results
Considering that upregulation of growth factor signaling
pathways and the loss of cell cycle regulators are common features
in glioblastoma multiforme [31], we address the role of HRas
V12
and/or Rb loss in conditional Rb murine astrocytes to explain the
tumor initiation and maintenance. To this purpose, conditional Rb
mutant mouse astrocytes were infected by retrovirus encoding
mutant Ras allele (HRas
V12) and the recombinase Cre that targets
the loxP sequences flanking exon 19 of the Rb gene [32]. Thus, we
managed to mimic the characteristic upregulation of EGFR and
FGFR signaling pathways by introducing a constitutively activated
isoform of Ras, and the cell cycle deregulation by genetically
inactivating the pocket protein Rb.
However, previous studies have reported that primary MEFs
enter senescence upon oncogenic stress induced by ectopic
expression of the oncogenic HRas
V12 [17,33]. Also, it has been
reported that the absence of pRb enables Ras activation
modulating differentiation in MEFs [34]. Accordingly, we carried
out several infection assays on MEFs where we observed that all
experimental groups enter senescence after HRas
V12 expression
(data not shown), as others reported.
Unexpectedly, we observed that the astrocytes infected with
PIG-Cre/pBABE-HRas
V12 retroviral vector (hereafter cRb
2/2/
Ras
V12) showed after one week an increased proliferation rate
when compared with the remaining groups. Astrocytes infected
with PIG-Cre/pBABE (hereafter cRb
2/2) and PIG/pBABE
(hereafter cRb
loxP/loxP) were used as control groups. To our
surprise, astrocytes infected with PIG/pBABE-HRas
V12 (hereafter
cRb
loxP/loxP/Ras
V12) also displayed a dramatic increment when
compared with the control group, although at a less extent than
cRb
loxP/loxP/Ras
V12 astrocytes. Proliferative differences between
astrocytic populations can be easily spotted in Figure 1A. To
further support these data, we carried out a BrdU incorporation
assay on all of the experimental groups, as shown in Figures 1B
and 1C, that confirmed our initial observation.
These data is compatible with the observation that both cRb
loxP/
loxP/Ras
V12 and cRb
2/2/Ras
V12 groups did not show SA-b-Gal
positive staining (Figure 1E), either in the presence or absence of
pRb. Thus, our findings suggest that oncogenic Ras alone,
regardless of pRb status, is sufficient to increase proliferation in
astrocytes and at the same time, circumvent the oncogene-induced
senescence seen in MEFs. Furthermore, Rb loss cooperates with
oncogenic Ras enhancing the growth rate but without inducing
senescence (Figures 1D and 1E) or apoptosis in astrocytes (data not
shown), as others previously reported in other cellular systems
[35].
Unlike normal primary astrocytes, flattened and non-refractile
cells, Ras-expressing astrocytes showed noticeable morphological
changes and loss of contact inhibition, and although flat cells were
also present, the population was heterogeneous and large
displaying at the same time a refractile cytoplasm with thin and
long projections (Figure 2A). It is also revealing the fact that
although Rb-deficient astrocytes displayed a marked proliferative
increase its morphology did not appear significantly changed. On
the contrary, Ras-expressing astrocytes seemed to undergo
dramatic morphological alterations suggesting a transformed
phenotype. We then wondered if these astrocytes would also
exhibit foci growth, which is a characteristic feature of transformed
cells. As Figure 2B shows, HRas
V12 seems to induce foci growth as
seen in cRb
loxP/loxP/Ras
V12 and cRb
2/2/Ras
V12 cells, whereas the
remaining groups do not show significant foci formation.
To further support the hypothesis concerning the transformed
status of these cells, we injected subcutaneously all the experi-
mental groups in SCID mice. cRb
loxP/loxP/Ras
V12 astrocytes
formed detectable tumors (N=2/13; p=NS) within 8–15 weeks
whereas tumors formed by cRb
2/2/Ras
V12 (N=13/13;
p,0.0001) appeared in-between the first and second week. No
tumors were observed in mice injected with cRb
loxP/loxP (N=0/11)
or cRb
2/2 (N=0/7) astrocytes (Figures 2C and 2D). Together,
our data suggest that HRas
V12 and Rb loss promote the
transformation of those cells. However, HRas
V12 alone is also
able to induce tumor growth in a minor extent and with a long
latency, suggesting that in this case a second oncogenic event is
needed to trigger tumorigenesis.
Histopathological examinations of the tumors generated from
cRb
2/2/Ras
V12 cells showed a high degree of vascularization
(Figure 2E) and necrotic regions surrounding the tumoral core,
caused by the chaotic cell growth observed in the tumoral
morphology resembling to those observed in human GBMs.
However, the tumors observed in mice injected with cRb
loxP/loxP/
Ras
V12 astrocytes bore a strong similarity with human low-grade
gliomas, showing moderate cellularity and few mitosis (Figure 2E).
Therefore, although in other cell systems like MEFs, [17,21,33] it
seems to be indispensable the loss of at least one tumor suppressor
to make cells more susceptible to Ras-induced hyper-replication
effects. In primary astrocytes, HRas
V12 oncogenic activity alone is
sufficient to unleash cellular hyper-proliferation but not in vivo
tumor formation. Then, Rb inactivation, besides enhancing
cellular growth in HRas
V12-expressing astrocytes (Figures 1A, 1B
and 1C), also confers a higher aggressiveness to the tumor
(Figures 2C and 2D).
As we previously described, although astrocytes harboring
HRas
V12 did not enter senescence we wanted to confirm whether
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associated with oncogene-induced senescence, was present. On the
other hand, HRas
V12 is also known to cause an increase in reactive
oxygen species (ROS) production [36] as a result of replication
stress. ROS has been traditionally considered as a toxic by-product
of cellular metabolism, but it has been appreciated that they are
actively involved in oncogenic signaling in cellular transformation
and cancer. Increased intracellular levels of ROS have also been
reported to mediate some biological effects of oncogenic HRas
V12,
such as the onset of premature senescence in primary cells, the
generation of genomic instability [37], and malignant transforma-
tion [38]. Furthermore, high levels of ROS have been detected in
several human cancer cell lines as well as in human tumors from
different tissues. Taken together these reports, we wanted to
analyze in astrocytes the relationship between oxidative stress and
glioma. We observed similar oncogene-induced ROS accumula-
Figure 1. Mouse astrocytes are defective for HRasv12-induced cell cycle arrest. a, Growth curve analysis of early-passage cRb
loxP/loxP
conditional astrocytes co-infected with PIG/pBABE (vector), PIG/pBABE-HRas
V12, PIG-Cre/pBABE and PIG-Cre/pBABE-HRas
V12 retroviral vectors. After
infection, cells were plated in triplicate and the cells were fixed on the indicated days for subsequent staining with crystal violet. Each time point
represents the mean6s.d. of total cumulative cell number from at least three independent experiments. b, Measurement of the proliferation of
astrocytes by BrdU incorporation assay (panel c). c, Cells were labeled with BrdU for 5 h on day 5 after puromycin selection. d, Senescence assays in
cRb
loxP/loxP and cRb
2/2. The y-axis represents the percentage of SA-b-galactosidase-positive cells (mean and s.d.) from at least three independent
experiments. e, A representative result of three independent experiments is shown. Photographs are at the same magnification.
doi:10.1371/journal.pone.0003632.g001
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loxP/loxP/Ras
V12 and cRb
2/2/Ras
V12 astrocytes, but
not in those that had lost only Rb (Figure 3A). Likewise, we found
signs of chromosomal instability (Figure 3B–D) in the groups that
expressed HRas
V12 and displayed ROS accumulation. One of the
most remarkable features of cRb
loxP/loxP/Ras
V12 and cRb
2/2/
Ras
V12 astrocytes is the abundance of centromeric instability
manifested as centromere fragments (CF) (Figure 3D and Figure
S1). We also found Robertsonian centromere fusion (Rob) in
cRb
loxP/loxP/Ras
V12 and cRb
2/2/Ras
V12 astrocytes but not in
cRb
2/2 and wildtype astrocytes (Figure S1). In addition, there
were numerical chromosome abnormalities in the experimental
groups that expressed oncogenic Ras. These astrocytes presented
.80 chromosomes per cell, doubling the chromosome number
found in control cells (Figure 3B and 3C). Hence, these numerical
and structural chromosome abnormalities show that activated Ras
is sufficient to induce chromosomal instability in the absence of
other signals, suggesting that Ras-induced chromosomal instability
arises as consequence of ROS accumulation and DNA replication
Figure 2. HRas
V12 in the absence of Rb induces malignant transformation both in vitro and in vivo.a ,Ability to form foci, representative
pictures of wells stained with crystal violet (day 7). b, Representative pictures of wells stained on the indicated days of culture showing the
morphological change observed in each group are also shown. c, Tumor-free survival curve (Kaplan-Meier plot) for tumor formation in SCID mice.
Tumor was found in cRb
2/2/Ras
V12 cohort (P,0.0001) d, Photographs of SCID mice after subcutaneous injection of cRb
loxP/loxP/Ras
V12 and cRb
2/2/
Ras
V12 astrocytes at eleven and two weeks respectively. Actual sizes of tumors after biopsy. e. Low-grade gliomas (cRb
loxP/loxP/Ras
V12; H&E, upper left)
showed a rather monomorphic appearance, with polygonal or rounded cell shape and smaller rounded nuclei without prominent nucleoli. Note the
absence of mitosis and necrosis. In contrast, high-grade gliomas (cRb
2/2/Ras
V12; H&E, lower left) displayed cellular pleomorphism, with large, fusiform
and irregular nuclei that frequently exhibit mitotic figures (upper left corner) and necrotic foci (lower right corner). Co-expression of EGFP permits the
visualization of the previously modified astrocytes.
doi:10.1371/journal.pone.0003632.g002
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cRb
loxP/loxP/Ras
V12 and cRb
2/2/Ras
V12 astrocytes implying that
the absence of pRb has not effect on DNA lesions, either
quantitative or qualitative.
These observations suggest that the presence of DNA lesions
may trigger DDR activation. Although the mechanisms that
generate DNA damage put in place by different oncogenic events
are unclear presently, Ras activation induces not only ROS-
induced DNA damage but also re-replication, an event known to
cause DDR activation [21]. DDR is likely to be related to
premalignant neoplastic lesions in human [18,39–41], and has
been linked to increased expression levels of p16
INK4A and p19
ARF
[18], which appear mutated in a vast proportion of GBMs [31].
Consequently, and considering that these cells were proliferating,
we expected these DDR checkpoints to appear down-regulated.
Surprisingly, we observed a rise of p16
INK4A, p19
ARF and p21
CIP1
expression levels in HRas
V12-expressing astrocytes despite of the
lack of senescence induction. Accordingly, detection of p-p53
Ser15
and phosphorylated histone c-H2AX in HRas
V12 expressing cells
suggested DNA damage induced by the Ras-driven DNA hyper-
replication (Figure 4A). Moreover, protein levels and their
phosphorylation status were significantly higher in cRb
2/2/
Ras
V12 astrocytes than cRb
loxP/loxP/Ras
V12 indicating that cRb
2/
2/Ras
V12 cells showed higher checkpoint activation (Figure 4A).
This difference can be explained by the fact that Rb inactivation
is able to trigger this response in a DNA damage-independent
manner. Recently, it has been shown that DNA damage-resistant
glioma cells show preferential activation of DDR contributing to
an increased survival of these cells [42]. This response may be
initiated by the recruitment of repair factors to the site of DNA
damage to form a multiprotein repair complex. The activation of
this response does not require DNA lesions [43,44], which may be
readily repaired in Rb-deficient cells due to the elevated levels of
repair factors activated in these responses. In fact, loss of pRb may
deregulate cell cycle checkpoints, allowing the propagation of
deleterious mutations, such as the ones produced by Ras-induced
hyper-replication to promote tumor progression [29,45]. Interest-
ingly, several studies have reported the instrumental role of p107
in compensating the Rb loss, thus preventing the cell to undergo
transformation [33,46]. However, up-regulation of this pocket
protein due to Rb inactivation apparently has a null effect on Ras-
expressing astrocytes (Figures 4A and S2).
Also, p38MAPK has been reported to function downstream
DNA damage sensors such as ATM and ATR after genotoxic
insult [47]. Besides that, the p38MAPK pathway is known to
become activated upon cellular stress, blocking proliferation or
promoting apoptosis [23–25,48,49]. p38MAPK mediates multiple
cellular processes but apparently its role in stress response is one of
the key factors in Ras-induced senescence. Thus, p38MAPK acts
as a sensor of oxidative stress during the initiation of tumorigenesis
and regulates negatively malignant transformation induced by
oncogenic Ras [25]. Given that, we wanted to know how
p38MAPK is regulated in our model.
Therefore, we next investigated whether p38MAPK phosphor-
ylationis raised inresponse to different oncogenic stimuli in cRb
loxP/
loxP astrocytes. Thus, we observed that Ras induced p38MAPK
activation (Figure 4B and Figure S3). Curiously, when the
expression of oncogenic Ras is combined with Rb deletion the
levels of activated p38MAPK are depleted. In the view of ROS
levels described above (Figure 3A), we expected similar p38MAPK
activation both in cRb
loxP/loxP/Ras
V12 and cRb
2/2/Ras
V12 groups.
The first specific phosphatase of p38MAPK to be identified was
Wip1 [50]. Wip1 is a serine/threonine phosphatase of the type 2C
protein phosphatase family (PP2C). This family of phosphatases,
highly conserved in eukaryotes, is frequently associated with
regulation of cellular stress responses [51]. An important amount
of data published in the last years suggests that Wip1 is an
oncogene. This phosphatase cooperates with other oncogenes to
transform murine embryonic fibroblasts [52]. Recently, it has been
reported that E2F-1 down-regulates p38MAPK signaling pathway
through E2F-induced up-regulation of Wip1 [30]. Accordingly, in
our experimental setting Rb-null glial cells showed increased levels
of this phosphatase, which explains the down-regulation of
phosphorylated p38MAPK (Figure 4B).
To further validate our observations, human low- and high-
grade glioma sections were labeled for this marker. High levels of
Wip1 expression correlate with high-grade tumors (Figure 4C).
Also, to test our hypothesis regarding the Ras-pRb loss
cooperation mediated by Wip1 all experimental groups were
treated with two chemical inhibitors upon infection, CCT007093
[57] and Arsenic Trioxide [58]. As a result, dephosphorylation of
p38MAPK by Wip1 was blocked as demonstrated by the increased
level of phosphorylated p38MAPK, especially in the cRb
2/2/
Ras
V12 group (Figure 5A). This biochemical outcome correlates
with the positive staining observed in SA-b-Galactosidase assays
(Figure 5B). In addition, proliferation rates observed in cRb
loxP/
loxP/Ras
V12 and cRb
2/2/Ras
V12 treated groups were significantly
lower that the same cells without treatments (Figure S4),
confirming previous reports where Ppm1d
2/2 MEFs showed
reduced proliferation rate with features of early senescence [52].
Discussion
Collectively, our results show that astrocytes expressing
oncogenic Ras display a strong proliferation in the absence of
senescence, facilitating their transformation into tumoral cells both
in vitro and in vivo. This observation has not been established in
other lineages, where OIS blocks tumor progression [17,48]. In
addition to that, the activation of DNA damage checkpoint
response detected in these cells raises some questions about the
kind of relationship that DDR holds with OIS. Although it has
been reported that OIS is a consequence of the activation of DDR
[19–22] we observed that in astrocytes DDR activation does not
necessary lead to senescence. At the same time, the pRb
requirement for Ras-mediated transformation [53] was not found
in our model. Our data indicate that HRas
V12 is able to cooperate
with Rb loss in the tumor malignization. This cooperation between
Ras and Rb loss opposes the conception that pRb is an essential
mediator that links Ras-dependent mitogenic signaling to cell cycle
regulation [54].
Given that p38MAPK-deficient cells are sensitized to HRas
V12-
induced transformation [25] and although the inactivation of
Wip1 is related to the inhibition of tumorigenesis [55], our data
point out that the cooperation between Ras and loss of Rb could be
due to the increase of Wip1 and consequently p38MAPK
inactivation. In this way, Rb loss in HRas
V12-expressing astrocytes
confers a double advantage. On one hand, Rb absence increases
the astrocytes proliferative rate but on the other hand, in a Rb
knock-out context, E2F-1 is activated and up-regulates both DNA
damage response in an DNA damage-independent manner,
favoring repair mechanisms, and Wip1 [30], leading to an
inactivation of p38MAPK and thus increasing cellular transfor-
mation. All of this may explain the low latency of cRb
2/2/Ras
V12
tumors versus cRb
loxP/loxP/Ras
V12 tumors and the high Wip1
expression observed in high-grade human gliomas. Interestingly
enough, Wip1 chemical inhibition in cRb
2/2/Ras
V12 astrocytes
leads to a significant fall in the proliferative rate of these cells,
which eventually enter senescence as opposed to cells where Wip1
Uncoupling DDR and OIS
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of selective therapeutic inhibitors targeting Wip1 as a promising
treatment for different types of cancer [56–58]. This study sheds
new lights on the possible mechanisms behind the progression
from preneoplastic lesions to malignant tumors (Figure 6), and
according to our glioma model identifies Wip1 as a potential
druggable target for new therapeutic approaches for a tumor
whose bad prognosis has not significantly changed over the past
two decades.
Materials and Methods
Cell culture and SA b-Galactosidase assay
Astrocytes were generated from cRb
loxP/loxP neonatal mice at
day 3. The care and use of all experimental animals was in
accordance with institutional guidelines. Cells were maintained in
Dulbecco modified Eagle medium (Sigma) with 10% fetal bovine
serum, 1% L-glutamine, and 1% penicillin/streptomycin
(GIBCO-Invitrogen). For introduction of an activated Ras allele
and Rb loss into astrocytes, Phoenix-Eco packaging cells (a gift from
G.P. Nolan) were transfected with pBABE, pBABE-HRas
V12,
PIG-puro and PIG-CRE retroviral plasmids (a gift from P.P.
Pandolfi). SA-b-galactosidase activity was assessed with the
Senescence b-Galactosidase Staining Kit (Cell Signaling).
Immunoblot
Cultures were washed twice in ice-cold PBS, lysed in ice-cold
RIPA buffer (16 PBS, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% SDS, 10 mg/ml PMSF, 40 mg of aprotinin/
ml, 100 mM orthovanadate). Analysis of protein levels was carried
out by immunoblot analysis using polyclonal antibodies (Abs)
against p53 (CM5; Novocastra), p-p53 ser15 (9284; Cell
Signaling), p19ARF (ab80; Abcam), p38 (C-20; Santa Cruz), p-
p38 (Thr180/Tyr182) (sc-17852; Santa Cruz), p16 (M-156; Santa
Cruz), p107 (C-18; Santa Cruz), p-H2AX Ser139 (07-164 Upstate)
and WIP-1 (H-300; Santa Cruz) and the monoclonal antibodies
pan-Ras (Ab-3; Calbiochem), pan-Ras-V
12 (Ab-1; Calbiochem),
anti-a-Tubulin (T5168; Sigma) and Rb (554136; BD). Densito-
Figure 3. HRas
V12-dependent production of reactive oxygen species (ROS) and associated chromosomal instability. a, cells were
assayed for dihydroethidium (DHE) fluorescence, indicative of ROS production and visualized by fluorescent microscopy. Under identical imaging
conditions, DHE oxidation was significantly increased in cRb
loxP/loxP/Ras
V12 and cRb
2/2/Ras
V12 astrocytes. b, cRb
2/2/Ras
V12 and cRb
loxP/loxP/Ras
V12 cells
are significantly more aneuploid than cRb
loxP/loxP and cRb
2/2 cells. c, Absolute chromosome numbers of cRb
loxP/loxP,c Rb
loxP/loxP/Ras
V12,c Rb
2/2 and
cRb
2/2/Ras
V12 cells, showing the presence of diploid and tetraploid populations. Representative data of at least three independent experiments. d,
Band G (Wright S) and telomere fluorescence in situ hybridization (T-Fish) was performed using a Cy3-labeled peptide nucleic acid (PNA) telomeric
probe. Representative metaphase spreads from cRb
loxP/loxP and cRb
2/2, partial representative metaphase spreads from cRb
loxP/loxP/Ras
V12 and cRb
2/2/
Ras
V12 stained with Wright and hybridized with Cy3 telomeric probe are shown. The regions of metaphase spreads from cRb
loxP/loxP/Ras
V12 and cRb
2/
2/Ras
V12 are magnified in the lower panel to show centromere fragments (CF), acentric fragment (AF), chromatide type break (CTB), telomeric fusion
(TF), robertsonian translocation (Rob) and other type of translocation (T). X indicates quadrivalent (Qua) found in cRb
loxP/loxP/Ras
V12.
doi:10.1371/journal.pone.0003632.g003
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(Silk Scientific, UT, USA).
Immunohistochemistry
Twenty cases of human astrocytomas, ten low-grade (grades I–
II) and ten high-grade (grade III–IV), were retrieved from the files
of the Pathology Department of the Clinical University Hospital,
Santiago de Compostela, Spain. The tumors had been diagnosed
according to standard criteria from the last WHO classification.
Two tissue microarrays (TMAs) were constructed from these cases
using a Tissue Arrayer device (Beecher Instruments, Sun Prairie,
WI). Two selected 1.5-mm diameter cylinders from two represen-
Figure 4. Rb loss enhances DNA damage response (DDR) induced by oncogenic Ras and reduces the p-p38MAPK levels by
upregulation of Wip1. a, HRas
V12 is able to induce DDR markers expression, such as p16
INK4a, p21
Cip1 and p19
ARF, p53 and p53
ser15 and c-
H2AX
ser139. Rb loss, in the presence of oncogenic Ras, increases this response. Immunoblot analysis was performed on astrocytes lysates prepared at
day 6 after co-infection and selection with puromycin. b, Immunoblot analysis of p-p38MAPK and Wip1 levels was performed on cell lysates prepared
at day 5 from co-infection and selection with puromycin. Densitometric analysis (in relative densitometric units) of Wip1 and p-p38MAPK protein
levels. c, TMA analysis of Wip1 expression in glioma clinical samples. Representative pictures of samples are shown. The table shows median values.
Wip1 immunoreactivity intensity was assigned according to the following scale: NA, non-assessable cases; 2, less than 10% of neoplastic cells
displayed immunoreactivity; +, 11–29% of neoplastic cells displayed immunoreactivity; ++, 30% or greater percentage of neoplastic cells displayed
immunoreactivity. Phospho-histone H3 was used as a proliferation marker. Scale bars, 50 mm.
doi:10.1371/journal.pone.0003632.g004
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Internal and external appropriate controls were included in each
TMA. TMA blocks were sectioned to produce 4-mm sections.
Immunohistochemistry was performed using a universal second
antibody kit that used a peroxidase-conjugated labeled-dextran
polymer (Envision Plus, Dako, Denmark). The following primary
antibodies were used: Wip1 (polyclonal, Santa Cruz Biotechnol-
ogy, USA), phospho-histone H3 (polyclonal, Cell Signaling
Technology) and p-p38 (polyclonal, Santa Cruz Biotechnology).
Prior to immunostaining, antigen retrieval was performed by the
sections in buffer by 20 min (Tris-EDTA pH 9 for Wip1 and p-
p38, citrate buffer pH 6 for H3). Overnight incubation at 4uC was
performed with every antibody.
Metaphase chromosome preparation and FISH
Metaphase spreads were prepared from exponentially growing
cells after treatment with colcemid (0.1 mg/ml) for 7 hr. Cells were
incubated in hypotonic buffer (0.05 M KCl, 0.0034 M trisodium
citrate) for 20 min at 37uC and fixed 75% methanol, 25% acetic
acid. Cells were then spotted onto microscope slides and stained
with 2% Wright in Gurr buffer (pH 7.0). Metaphase chromosomes
were scored using a Leica 2005 microscope under a 1006 oil
objective lens. At least 50 metaphases were analyzed from three
independent experiments. TFISH was performed on unstained
metaphase chromosomes using a Cy3- labeled peptide nucleic acid
probe. For T-FISH, both the DNA probe and the slides were heat
denatured (80uC for 5 min) and hybridized at 37uC for 2 hr
accordance with the manufacturer’s specifications (Dako Cytoma-
tion). Slides were counterstained with DAPI, and the images were
captured using a Leica 2005 microscope equipped with the
software program by Leica 4000.
Wip1 inhibition treatment
cRb
loxP/loxP conditional astrocytes were co-infected with PIG/
pBABE, PIG/pBABE-HRasV12, PIG-Cre/pBABE and PIG-
Cre/pBABE-HRas
V12 retroviral vectors. Cells were plated in
triplicate and treated either with CCT007093 (Maybridge,
Figure 5. Wip1 inhibition enables senescence in cRb
2/2/Ras
V12 astrocytes. a, All the experimental groups were treated with the Wip1
chemical inhibitors CCT007093 and Arsenic Trioxide (ATO). Levels of p-p38MAPK were assessed by Western blot analysis as a readout of Wip1
phosphatase activity inhibition. b, SA-b-galactosidase assays in all groups (without treatment, ATO treatment, CCT007093 treatment). The y-axis
represents the percentage of-positive cells (mean and s.d.).
doi:10.1371/journal.pone.0003632.g005
Figure 6. DDR is modulated by Rb loss switching premalignant
lesion to cancer.
doi:10.1371/journal.pone.0003632.g006
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upon infection at a concentration of 25 mM and 10 mM,
respectively. Subsequent cell fixation and crystal violet staining
were carried out in the indicated days.
Supporting Information
Figure S1 Telomere fluorescence in situ hybridization (T-FISH)
of metaphase spreads. Merged images of DAPI (blue) and
telomeric probe (red). The selected regions of metaphase spreads
from mouse astrocytes infected with HRASV12 are magnified to
show centromere fragments (CF) and Robertsonian centromeric
fusion (Rob), indicated by arrows.
Found at: doi:10.1371/journal.pone.0003632.s001 (3.00 MB TIF)
Figure S2 Acute deletion of Rb in astrocytes and analysis of pRb
and p107 levels. Immunoblot analysis of proliferating cRbloxP/
loxP astrocytes after infection at day 1 and 6 post-selection with
puromycin. pRb was no longer detectable at day 1 after selection.
The pRb family member p107 was significantly affected by loss of
pRb. Compensation of pRb loss by p107 presence is already
present at day 1.
Found at: doi:10.1371/journal.pone.0003632.s002 (3.00 MB TIF)
Figure S3 Acute deletion of Rb in astrocytes and the effect on
Wip1 and pp38 levels. Immunoblot analysis of proliferating cRb
loxP/loxP astrocytes after infection at day 1 and 6 post-selection
with puromycin. The lower level of pp38 is shown after 7 days but
not at day 1 after selection.
Found at: doi:10.1371/journal.pone.0003632.s003 (3.00 MB TIF)
Figure S4 Wip1 inhibition decreases the proliferation rate in
cRb2/2/RasV12 astrocytes. All the experimental groups were
treated with the Wip1 chemical inhibitors CCT007093 and
Arsenic Trioxide (ATO). The relative cell number of early-passage
cRbloxP/loxP conditional astrocytes co-infected with PIG/
pBABE (vector), PIG/pBABE-HRasV12, PIG-Cre/pBABE and
PIG-Cre/pBABE-HRasV12 retroviral vectors, is shown. After
infection, cells were plated in triplicate and fixed on the indicated
days for subsequent staining with crystal violet. Each time point
represents the mean6s.d. of total cumulative cell number (without
treatment, ATO treatment, CCT007093 treatment).
Found at: doi:10.1371/journal.pone.0003632.s004 (3.00 MB TIF)
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